Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest

Condition(s) targeted: Cardiac Arrest

Intervention: epinephrine (1 mg/1 mL) (Drug); arginine-vasopressin (40 UI/2 mL) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Hospices Civils de Lyon

Official(s) and/or principal investigator(s):
Pierre-Yves GUEUGNIAUD, MD, Principal Investigator, Affiliation: Hospices Civils de Lyon

Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests. The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine. The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients. The primary endpoint is the survival rate at hospital admission. The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.

Official title: Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Primary outcome: Survival at hospital admission

Secondary outcome: ROSC (Return of spontaneous circulation) Survival at : H24, Day 28, hospital discharge and one year Neurological status at H24 and hospital discharge.

Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Out-of-hospital medical cardiac arrest in adult patients.

Exclusion Criteria:

- Traumatic cardiac arrest

- Pregnancy

- Patients younger than 18 years old or older than 85 years old

Centre Hospitalier Lyon Sud, Pierre Bénite 69495, France

Starting date: May 2004
Last updated: October 16, 2007